PT  - JOURNAL ARTICLE
AU  - Zhilkova, Anna
AU  - Lall, Ramona
AU  - Mathes, Robert
AU  - Chamany, Shadi
AU  - Olson, Donald
TI  - Diabetes related emergency department visits among adults during the COVID-19 pandemic – an analysis of data from the New York City syndromic surveillance system
AID  - 10.1101/2023.12.20.23300289
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.12.20.23300289
4099  - http://medrxiv.org/content/early/2023/12/21/2023.12.20.23300289.short
4100  - http://medrxiv.org/content/early/2023/12/21/2023.12.20.23300289.full
AB  - Objective New York City was an early epicenter of the COVID-19 pandemic. We aim to describe population level epidemiological trends in diabetes related emergency department (ED) visits among adults in New York City, for the period prior to and encompassing the first four waves of the pandemic.Research Design and Methods We used data from the New York City ED syndromic surveillance system during December 30, 2018 through May 21, 2022. This system captures all visits from EDs in the city in near-real time. We matched these visits to laboratory confirmed COVID-19 positivity data beginning with February 15, 2020.Results Compared to pre-pandemic baseline levels, diabetes related ED visits noticeably increased during the first wave in spring 2020, though this did not necessarily translate to net increases overall during that period. Visits for diabetic ketoacidosis, particularly among adults with type 2 diabetes, sharply increased before returning to pre-pandemic levels, most notably during wave 1 and wave 4 in winter 2021-2022. Trajectories of diabetes-related ED visits differed by diabetes type, age, and sex. Some ED visit trends did not return to pre-pandemic baseline levels.Conclusions The COVID-19 pandemic, especially the first wave in the spring of 2020, coincided with a dramatic shift in diabetes related ED utilization in New York City. Our findings highlight the importance of on-going surveillance of health care utilization for chronic diseases during population-level emergencies like pandemics. A robust syndromic surveillance system that includes infectious and non-infectious syndromes is useful to better prepare, mitigate, and respond to population-level events.Article HighlightsDiabetes related emergency department (ED) visits in New York City increased dramatically with the emergence of the COVID-19 pandemic in spring 2020.The trajectory of diabetes-related ED visits differed by diabetes type, age, sex, and pandemic wave.The diabetes complication of diabetic ketoacidosis among adults with type 2 diabetes showed sharp increases in the first and fourth waves of the pandemic, respectively its initial emergence in spring 2020 and the Omicron variant in winter 2021-2022.Our findings highlight the importance of on-going surveillance of health care utilization for chronic diseases during population-level emergencies like pandemics.Summary Data from NYC’s syndromic surveillance system showed major increases in #type2diabetes complications (e.g. diabetic ketoacidosis) during #COVID-19 waves 1 and 4 (Omicron) – this tool may be useful for population-level monitoring of chronic disease complications during emergenciesCompeting Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was classified as public health surveillance and exempt from ethical review and informed consent by the Institutional Review Board of the New York City Department of Health and Mental Hygiene. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors through signed Data Use Agreement with the New York City Department of Health and Mental Hygiene, as required by Department of Health and Mental Hygiene guidelines.